Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
The rise in serum gastrin and pepsinogen I after 5 days' treatment with the proton pump inhibitor pantoprazole (40 mg/day) was examined in eight duodenal ulcer patients with Helicobacter pylori infection and compared with eight in whom it had been eradicated. Before treatment, the post-prandial serum gastrin concentrations were higher in the H. pylori-positive than -eradicated patients (p less than 0.05). The median rise in pre-prandial serum gastrin concentrations on treatment was similar in the H. pylori-positive (41%) and -eradicated patients (45%). The rise in post-prandial serum gastrin was also similar in the H. pylori-positive (81%) and -eradicated patients (69%), resulting in significantly higher gastrin concentrations during treatment in the former. The median rise in serum pepsinogen I on treatment was greater in the H. pylori-positive (114%) than in the -eradicated patients (8%), resulting in significantly higher concentrations during treatment in the former. These observations indicate that eradication of H. pylori may be a means of moderating the hypergastrinaemia caused by acid-inhibitory therapy. They also indicate that H. pylori-related hypergastrinaemia is not due to an increase of the antral surface pH by the bacterium's urease activity.
McColl
K E
KE
University Dept. of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland.
Nujumi
A M
AM
Dorrian
C A
CA
Macdonald
A M
AM
Fullarton
G M
GM
Harwood
J
J
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors*; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D005745:Gastric Acidity Determination; D005755:Gastrins / Q000097:blood* / Q000187:drug effects; D016481:Helicobacter Infections / Q000097:blood* / Q000378:metabolism; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D020116:Pepsinogen A; D010435:Pepsinogens / Q000097:blood* / Q000187:drug effects; D010446:Peptide Fragments / Q000097:blood* / Q000187:drug effects; D013454:Sulfoxides / Q000494:pharmacology* / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D005755:Gastrins; D010435:Pepsinogens; D010446:Peptide Fragments; D013454:Sulfoxides; C037980:pepsinogen (1-12); D020116:Pepsinogen A; D000077402:Pantoprazole; D000251:Adenosine Triphosphatases; D009853:Omeprazole